Anastrozole increases predicted adult height of GH-deficient adolescent boys
This article has no abstract so we have provided the first paragraph of the full text.
Estrogen is a principal regulator of epiphyseal fusion in females and males. Mauras et al. conducted a double-blind, randomized, placebo-controlled trial to determine whether estrogen suppression with the selective aromatase inhibitor anastrozole, administered to growth hormone (GH)-deficient adolescent boys who were also receiving GH therapy, delays epiphyseal fusion (and, therefore, retards bone-age advancement) and whether it increases predicted adult height.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
